We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PFIZER TO CONDUCT MORE STUDIES ON BEXTRA PAINKILLER
PFIZER TO CONDUCT MORE STUDIES ON BEXTRA PAINKILLER
October 18, 2004
Pfizer has announced it will conduct additional long-term studies to assess the cardiovascular safety of its Cox-2 inhibitor, Bextra, as well as update the product’s labeling to include a stronger warning for serious skin rashes that have occurred in some patients taking the drug.